Similarly, lung and melanoma patient-derived xenografts treated with inhibitors of the MAPK signalling pathway developed amplifications of the BRAF gene, which allowed the bypass of the targeted oncogene inhibition (Xue et al. 2017). The gene discussed is BRAF; the disease is melanoma.